Normal view

Received — 10 September 2026 ⏭ Molecular Therapy Nucleic Acids

Molecular Therapy Nucleic Acids
An mRNA–lipid nanoparticle vaccine targeting the Plasmodium vivax E140 antigen Rodolfo Ferreira Marques · Guilherme Antonio de Souza-Silva · Vitor Antunes da Silva · András Sárközy · Máté Vadovics · Hiromi Muramatsu · Edit Ábrahám · Carolina Bioni Garcia · Silvia Beatriz Boscardin · Rachel H.J. Jun · Anna Caroline Campos Aguiar · Zoltan Lipinszki · Norbert Pardi · Daniel Youssef Bargieri
Immunization with a nucleoside-modified mRNA-LNP vaccine encoding the conserved malaria antigen E140 induced durable humoral immunity in mice and generated invasion-blocking antibodies against Plasmodium vivax. The results highlight E140 as a promising candidate for next-generation malaria vaccines.
2 September 2026 at 08:00

An mRNA–lipid nanoparticle vaccine targeting the Plasmodium vivax E140 antigen

By: Rodolfo Ferreira Marques · Guilherme Antonio de Souza-Silva · Vitor Antunes da Silva · András Sárközy · Máté Vadovics · Hiromi Muramatsu · Edit Ábrahám · Carolina Bioni Garcia · Silvia Beatriz Boscardin · Rachel H.J. Jun · Anna Caroline Campos Aguiar · Zoltan Lipinszki · Norbert Pardi · Daniel Youssef Bargieri

2 September 2026 at 08:00

Immunization with a nucleoside-modified mRNA-LNP vaccine encoding the conserved malaria antigen E140 induced durable humoral immunity in mice and generated invasion-blocking antibodies against Plasmodium vivax. The results highlight E140 as a promising candidate for next-generation malaria vaccines.